RET E632_L633del

CI-VAR-00000804Explore in graph →NP_066124.1:p.Glu632_Leu633delNM_020975.6:c.1894_1899delClinVar 376313 CIViC 4785 rs121913312

Curated evidence

Evidence by cancer (10 items)

Grouped by cancer context first, then therapy. The same variant can be sensitizing in one cancer and irrelevant in another — contexts are never merged. 50 items per page; a cancer group may continue on the next page.

civicCuratedShowing 1–10 of 10 evidence items across 2 cancer contexts on this page · levels, directions and significance as curated at the source; each row links to its CIViC record.

Molecular profile	Therapy	Type	Level	Direction · significance	Rating (1–5)	Status	Evidence	Source
Malignant Neoplasm6
RET E632_L633del	(oncogenic)	Oncogenic	D	Supports Oncogenicity	3	accepted	EID11873 A RET c.1894_1899del p.E632_L633del mutation was identified in a 32-year-old patient with a particularly aggressive medullary thyroid cancer. This mutation removes 2 amino acids adjacent to the cyste… (full text at CIViC) PMID 9191060 · Ceccherini et al., 1997 · Open in CIViC	civic
RET E632_L633del	(oncogenic)	Oncogenic	D	Supports Oncogenicity	3	submitted	EID12713 Exogenous expression of RET E632_L633del transformed Ba/F3 cells, causing interleukin-3 independent proliferation. This proliferation was abolished with various RET inhibitors. PMID 37376747 · Szymczak et al., 2023 · Open in CIViC	civic
RET E632_L633del

ClinVar

Clinical significance (1)

ClinVar interpretations are shown as structured records — significance, review status, star rating, conditions — never flattened into one word.

clinvarCurated1 interpretation · review status and star rating as assigned by ClinVar.

Variation	Clinical significance	Review status	Stars	Conditions	Origin	Submitters	Last evaluated	Source
376313	Uncertain significance	criteria provided, single submitter	1	Multiple endocrine neoplasia, type 2	germline	1	Oct 16, 2019	clinvar

Thyroid Gland Medullary Carcinoma4
RET D898_E901del AND RET E632_L633del	(oncogenic)	Oncogenic	C	Supports Oncogenicity	1	submitted	EID12710 In a study of 56 Medullary Thyroid Cancer patients (50 somatic and 6 hereditary) two patients had somatic p.E632_L633del. One of them had p.E632_L633del and p.D898_E901del found in lymph node metasta… (full text at CIViC) PMID 29515777 · Romei et al., 2018 · Open in CIViC	civic
RET E632_L633del	Selpercatinib	Predictive	B	Supports Sensitivity Response	3	accepted	EID11875 Among 319 medullary thyroid cancer patients enrolled in the LIBRETTO-001 trial, 9 patients harbored the RET p.E632_L633del mutation (c.1894_1899delGAGCTG) in their tumor. After treatment with the sel… (full text at CIViC) PMID 37376747 · Szymczak et al., 2023 · Open in CIViC	civic
RET E632_L633del	Selpercatinib	Predictive	C	Does Not Support Sensitivity Response	2	submitted	EID12714 A 35 yr old man presented with a 9 month history of worsening right side flank pain and no significant family history. Calcitonin was elevated. After imaging, total thyroidectomy with modified radica… (full text at CIViC) PMID 36416226 · Wijewardene et al., 2023 · Open in CIViC	civic
RET E632_L633del	Selpercatinib	Predictive	C	Supports Sensitivity Response	3	submitted	EID12716 A patient with advanced progressive medullary thyroid cancer and distant metastatic disease harbored the somatic RET E632_L633del indel and was treated under the LIBRETTO-201 (NCT03906331) trial. Selp… (full text at CIViC) PMID 35616103 · Elisei et al., 2022 · Open in CIViC	civic